INSIGHTS ON DRUG DEVELOPMENT

• Why Emerging Drug Developers Can't Afford To Delay Analytical Development

  Rushing early pharma development by neglecting quality and analytical frameworks risks regulatory failures, clinical holds, and expensive rework.

• What Is DMPK, And Why Does It Matter In Drug Development?

  By leveraging advanced DMPK software solutions, you can streamline your workflows and make informed decisions with confidence.

• Fast And Scalable Fc Quantitation In Supernatants

  In biopharmaceutical development, the Fc PAIA Titer assay offers a fast, cost-effective, and automatable solution for high-throughput Fc quantification to enhance efficiency, support research, and accelerate production advancements.

• The Role Of CDMOs In Supporting Generic Drug Development

  Bringing complex generics to market requires deep expertise. Learn how a CDMO can help navigate regulatory, technical, and commercial challenges with end-to-end development and manufacturing support.

• Are You Keeping Pace With Oligo Synthesis Optimization?

  11/18/2025

  The rapidly expanding oligo market demands optimized RNA synthesis. Examine key innovations and workflow insights to maximize resources and control long-term manufacturing costs.

• Bioprocess Optimization: Leveraging Functional DOE With Time-Based Insights

  3/5/2025

  Explore the key differences between traditional DOE and Functional DOE as Seongjin Kim demonstrates how the latter enhances bioprocess optimization through a fed-batch cell culture example.

• Imagine The Future: An Enhanced Oligonucleotide Synthesis Process

  2/9/2026

  Gain practical guidance for improving oligo quality, see how an advanced synthesis platform supports production, and explore a software interface designed to make daily operations more intuitive.

• Payload-Linker CMC Services High-Potency R&D And GMP Manufacturing

  6/11/2026

  A closer look at how advanced containment, continuous processing, and integrated CMC workflows help address payload–linker challenges, improve safety, and enable scale-up of antibody–drug conjugates.

• Developing High Concentration Biopharmaceuticals: Formulation Considerations

  9/11/2024

  This session addresses key obstacles—such as opalescence, viscosity, and aggregation—and presents case studies on how composition changes during the concentration process can be effectively characterized.